AlphAIalphai — Financial news for AI agents
Stock TitanMAY 202 min read$TNYA

Tenaya (TNYA) CEO sells 3,390 shares tied to RSU tax withholding

Tenaya Therapeutics CEO Ali Faraz sold 3,390 shares of common stock at $0.7934 per share on May 18, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. After this transaction, Faraz directly holds 440,014 shares, which includes 321,581 shares that will be issued upon future RSU vesting. This sale is identified as being for tax purposes rather than a reduction in long-term holdings.

Original reporting
Stock Titan
Published May 20, 2026, 12:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 20, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TNYA
Neutral
medium confidence
Mentioned
$TNYA
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$TNYANeutralLow
01

Why it matters

This transaction is routine and unlikely to influence investor perception or stock price significantly.

02

Market read

The event has minimal impact on market perception; primarily a personal tax-related transaction.

03

What to watch

The sale does not reflect a change in insider confidence or company outlook; consider broader insider activity and company fundamentals for comprehensive assessment.

Timing: short-term

Background

The CEO sold shares to cover tax obligations related to RSU vesting, a common practice among executives.

Company-level read

Ticker impact

$TNYANeutralMedium confidence
Context

The transaction involves the CEO selling shares to cover tax obligations related to RSU vesting, which is a routine corporate event and may not directly reflect on the company's operational outlook.

Expected impact

Minimal to no immediate impact on stock price; likely to remain within recent trading range.

Evidence & confidence

Such sales are common for tax withholding and are not indicative of insider sentiment about the company's future performance.

Market effects

Sector

Limited; the event pertains specifically to insider tax-related share sale and does not affect sector fundamentals.

Regional

None; localized event with no regional market implications.

Global

Negligible; company-specific insider activity unlikely to influence global markets.

Counterpoint

What could challenge this read

Some investors might interpret insider sales as a cautious signal; however, in this context, it is primarily for tax purposes.

Key entities

  • Person
    Ali Faraz

    CEO of Tenaya Therapeutics

  • Company
    TNYA

    Tenaya Therapeutics Inc.

Read at source← All news

Related articles

AUG 18
$TNYAMed

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics (NASDAQ:TNYA) said it plans Q4 updates for gene therapy TN-401 in PKP2-associated ARVC, with early data showing ~60% to 67% PVC reductions across patients (up to 52 weeks). It also reported Phase 1 results for TN-301 (72 patients) and Phase 2-enabling work. Tenaya had ~$78M cash and a $10M upfront Alnylam deal.

yahoo.com5 min
AUG 5
$TNYAMed

Tenaya Therapeutics, Inc. (TNYA): Results of Operations and Financial Condition

Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements

SEC EDGAR 8-K6 min
JUN 3
$TNYAMedAI 9/10

Tenaya's TN-201 Gene Therapy Shows Sustained Cardiac Improvements In MYBPC3-Associated HCM

Tenaya Therapeutics reported interim MyPEAK-1 Phase 1b/2 data for TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. As of a May 2026 cutoff, six evaluable patients showed improvements in echocardiographic hypertrophy and symptom measures; three improved exercise capacity. Company said benefits were sustained up to two years in Cohort 1 and earlier in Cohort 2. PRIME and FDA rare disease processes apply.

rttnews.com4 min
AUG 18
$XOMMed

ExxonMobil $1.1bn pre-FID contracts for Rovuma LNG phase one

ExxonMobil Mozambique said it awarded about $1.1bn in pre-investment contracts for phase one of the Rovuma LNG project in Mozambique’s Area 4, covering long-lead subsea equipment, valves and offshore export line pipe. The awards were issued for Area 4 partners ENH, CNPC, Eni, KOGAS and XRG, supporting progress toward a final investment decision. The onshore plant is designed for ~18.6 mtpa LNG.

offshore-technology.com4 min
AUG 18
$LHXMed

Sam Mehta Named L3Harris President, CEO

L3Harris Technologies appointed Sam Mehta as president and CEO, effective immediately, and added him to the board. Christopher Kubasik stepped down as chairman and CEO after the company said it learned of conduct inconsistent with its code of conduct. Lewis Hay III became independent chairman. Lauren Barnes and Christopher Aebli took over Mehta’s prior segments; L3Harris reiterated a $3 billion capital buildout.

govconwire.com4 min
AUG 18
Med

Einride to deploy 500 Tesla electric trucks for North American fleet

Einride AB said it will deploy 500 Tesla electric trucks across its North American operations over the next two years, starting September 2026 and completing in phases through 2028. The company said the rollout would support customers including Amazon and triple its electric truck fleet. Einride also cited 19 million electric miles logged by its AI monitoring system and aims to convert about $800 million in potential annual recurring revenue into active capacity.

investing.com3 min